Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy

NCT07807995 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT07807995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
September 17, 2026
Completion date
December 28, 2029
Enrollment
605 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

immunoglobulin a nephropathy